Cytokinetics Announces Proposed Public Offering of Common Stock
May 08 2017 - 4:29PM
Cytokinetics, Incorporated (Nasdaq:CYTK) today announced plans to
offer, subject to market and other conditions, $75,000,000 of its
common stock in an underwritten public offering. There can be no
assurance as to whether or when the offering may be completed, or
the actual size or terms of the offering. The company expects to
grant the underwriter a 30-day option to purchase up to an
additional 15% of the number of shares of common stock sold in
connection with the offering. All of the shares of common stock in
the offering will be sold by Cytokinetics.
Morgan Stanley is acting as sole underwriter for
the offering. A registration statement related to the offering has
been filed with the Securities and Exchange Commission. A
preliminary prospectus supplement and final prospectus supplement,
when available, may be obtained from the offices of Morgan Stanley
& Co. LLC, Attention: Prospectus Department, 180 Varick Street,
2nd Floor, New York, NY 10014.
This press release shall not constitute an offer
to sell or the solicitation of an offer to buy, nor shall there be
any sale of these securities in any state or jurisdiction in which
such offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of any such
state or jurisdiction. Any offer, if at all, will be made only by
means of a prospectus, including a prospectus supplement, forming a
part of the effective registration statement.
About Cytokinetics
Cytokinetics is a late-stage biopharmaceutical
company focused on discovering, developing and commercializing
first-in-class muscle activators as potential treatments for
debilitating diseases in which muscle performance is compromised
and/or declining.
Forward-Looking Statements
This press release contains forward-looking
statements, including statements relating to Cytokinetics’
expectations regarding the completion, timing and size of the
proposed public offering. These statements are subject to
significant risks and uncertainties and actual results could differ
materially from those projected. Cytokinetics cautions investors
not to place undue reliance on the forward-looking statements
contained in this release. These risks and uncertainties include,
without limitation, risks and uncertainties related to market
conditions and satisfaction of customary closing conditions related
to the public offering. There can be no assurance that Cytokinetics
will be able to complete the public offering on the anticipated
terms, or at all. Risks and uncertainties relating to Cytokinetics
and its business can be found in the “Risk Factors” section of
Cytokinetics’ Quarterly Report on Form 10-Q for the first quarter
of 2017, which was filed on May 4, 2017, and in the preliminary
prospectus supplement related to the proposed offering filed with
the SEC. Cytokinetics undertakes no duty or obligation to update
any forward-looking statements contained in this release as a
result of new information, future events or changes in
Cytokinetics’ expectations.
Contact:
Cytokinetics
Diane Weiser
Vice President, Corporate Communications, Investor Relations
(415) 290-7757
Cytokinetics (NASDAQ:CYTK)
Historical Stock Chart
From Aug 2024 to Sep 2024
Cytokinetics (NASDAQ:CYTK)
Historical Stock Chart
From Sep 2023 to Sep 2024